EO9 (Apaziquone)

From the clinic to the laboratory and back again

Roger M. Phillips, Hans R. Hendriks, Godefridus J. Peters

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic elimination and poor penetration through avascular tissue were the major factors responsible for EO9's poor efficacy. Based upon an understanding of why EO9 failed, a further clinical trial against patients with superficial transitional cell carcinoma of the bladder was conducted. The rationale for this was that intravesical administration directly into the bladder would circumvent the drug delivery problem, and any drug reaching the blood supply would be rapidly cleared thereby reducing the risk of systemic exposure. EO9 was well tolerated, and clinical activity against marker lesions was recorded in both phase I and II clinical trials. This article charts the pharmacological history of EO9 and discusses the potential implications that 'the EO9 story' has for the development of other loco-regional therapies.

Original languageEnglish
Pages (from-to)11-18
Number of pages8
JournalBritish Journal of Pharmacology
Volume168
Issue number1
Early online date18 Dec 2012
DOIs
Publication statusPublished - Jan 2013
Externally publishedYes

Fingerprint

apaziquone
Phase II Clinical Trials
Pharmaceutical Preparations
Urinary Bladder
History
Clinical Trials
Intravesical Administration
Clinical Trials, Phase I
Transitional Cell Carcinoma

Cite this

Phillips, Roger M. ; Hendriks, Hans R. ; Peters, Godefridus J. / EO9 (Apaziquone) : From the clinic to the laboratory and back again. In: British Journal of Pharmacology. 2013 ; Vol. 168, No. 1. pp. 11-18.
@article{344e0f11cdeb42aab99eb4f2a42c94f1,
title = "EO9 (Apaziquone): From the clinic to the laboratory and back again",
abstract = "EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic elimination and poor penetration through avascular tissue were the major factors responsible for EO9's poor efficacy. Based upon an understanding of why EO9 failed, a further clinical trial against patients with superficial transitional cell carcinoma of the bladder was conducted. The rationale for this was that intravesical administration directly into the bladder would circumvent the drug delivery problem, and any drug reaching the blood supply would be rapidly cleared thereby reducing the risk of systemic exposure. EO9 was well tolerated, and clinical activity against marker lesions was recorded in both phase I and II clinical trials. This article charts the pharmacological history of EO9 and discusses the potential implications that 'the EO9 story' has for the development of other loco-regional therapies.",
keywords = "Apaziquone, bioreductive prodrugs, bladder cancer, EO9, Eoquin, hypoxia, NQO1",
author = "Phillips, {Roger M.} and Hendriks, {Hans R.} and Peters, {Godefridus J.}",
year = "2013",
month = "1",
doi = "10.1111/j.1476-5381.2012.01996.x",
language = "English",
volume = "168",
pages = "11--18",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

EO9 (Apaziquone) : From the clinic to the laboratory and back again. / Phillips, Roger M.; Hendriks, Hans R.; Peters, Godefridus J.

In: British Journal of Pharmacology, Vol. 168, No. 1, 01.2013, p. 11-18.

Research output: Contribution to journalReview article

TY - JOUR

T1 - EO9 (Apaziquone)

T2 - From the clinic to the laboratory and back again

AU - Phillips, Roger M.

AU - Hendriks, Hans R.

AU - Peters, Godefridus J.

PY - 2013/1

Y1 - 2013/1

N2 - EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic elimination and poor penetration through avascular tissue were the major factors responsible for EO9's poor efficacy. Based upon an understanding of why EO9 failed, a further clinical trial against patients with superficial transitional cell carcinoma of the bladder was conducted. The rationale for this was that intravesical administration directly into the bladder would circumvent the drug delivery problem, and any drug reaching the blood supply would be rapidly cleared thereby reducing the risk of systemic exposure. EO9 was well tolerated, and clinical activity against marker lesions was recorded in both phase I and II clinical trials. This article charts the pharmacological history of EO9 and discusses the potential implications that 'the EO9 story' has for the development of other loco-regional therapies.

AB - EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic elimination and poor penetration through avascular tissue were the major factors responsible for EO9's poor efficacy. Based upon an understanding of why EO9 failed, a further clinical trial against patients with superficial transitional cell carcinoma of the bladder was conducted. The rationale for this was that intravesical administration directly into the bladder would circumvent the drug delivery problem, and any drug reaching the blood supply would be rapidly cleared thereby reducing the risk of systemic exposure. EO9 was well tolerated, and clinical activity against marker lesions was recorded in both phase I and II clinical trials. This article charts the pharmacological history of EO9 and discusses the potential implications that 'the EO9 story' has for the development of other loco-regional therapies.

KW - Apaziquone

KW - bioreductive prodrugs

KW - bladder cancer

KW - EO9

KW - Eoquin

KW - hypoxia

KW - NQO1

UR - http://www.scopus.com/inward/record.url?scp=84872835507&partnerID=8YFLogxK

UR - http://bpspubs.onlinelibrary.wiley.com/hub/journal/10.1111/(ISSN)1476-5381/

U2 - 10.1111/j.1476-5381.2012.01996.x

DO - 10.1111/j.1476-5381.2012.01996.x

M3 - Review article

VL - 168

SP - 11

EP - 18

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -